Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.41 |
| ▸ | TLR4 | O00206 | 1/20 | 0.40 |
| ▸ | TLR2 | O60603 | 1/20 | 0.40 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2208993 | 0.81 | RAB9A (0.60) | RAB9AKMT2ATDP1L3MBTL1MAOA | |
| SCHEMBL2207552 | 0.81 | RAB9A (0.60) | RAB9AKMT2ATDP1L3MBTL1MAOA | |
| SCHEMBL4569044 | 0.81 | RAB9A (0.60) | RAB9AKMT2ATDP1L3MBTL1MAOA | |
| SCHEMBL8903855 | 0.80 | MAOA (0.46) | RAB9AKMT2ATDP1L3MBTL1MAOA | |
| SCHEMBL2207764 | 0.80 | RAB9A (0.61) | RAB9AKMT2ATDP1L3MBTL1MAOA | |
| SCHEMBL4568943 | 0.80 | — | — | |
| SCHEMBL2207522 | 0.79 | FFAR4 (0.45) | TLR4TLR2FFAR4MTNR1AMTNR1B | |
| SCHEMBL4569100 | 0.78 | MAOA (0.42) | RAB9AKMT2ATDP1L3MBTL1MAOA | |
| SCHEMBL2205226 | 0.78 | RAB9A (0.61) | RAB9AKMT2ATDP1L3MBTL1TLR4 | |
| SCHEMBL2206902 | 0.78 | RAB9A (0.46) | RAB9AKMT2ATDP1L3MBTL1MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
| US-20210077427-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2021-03-18 | — | — | US | disclosed |
| US-10639286-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2020-05-05 | — | — | US | disclosed |
| US-20190183816-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2019-06-20 | — | — | US | disclosed |
| US-10188615-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2019-01-29 | — | — | US | disclosed |
| US-20180177746-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2018-06-28 | — | — | US | disclosed |
| US-20180177746-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2018-06-28 | — | — | US | disclosed |
| EP-3210966-A1 | ALKOXYPHENYLPROPYLAMINES FOR THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION | Acucela, Inc. (US) | 2017-08-30 | — | — | EP | disclosed |
| US-9737496-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-9737496-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2017-08-22 | — | — | US | disclosed |
| US-20120214852-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-08-23 | — | — | US | disclosed |
| US-20120129894-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120129894-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-24 | — | — | US | disclosed |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ACUCELA INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-7982071-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-7982071-B2 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2011-07-19 | — | — | US | disclosed |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ACUCELA INC. (US) | 2009-12-31 | — | — | US | disclosed |
| WO-2009045479-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. (US) | 2009-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122938-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | RAB9A 2120/4885KMT2A 3103/4885TDP1 499/4885 |
| US-20210077427-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | RAB9A 2120/4885KMT2A 3103/4885TDP1 499/4885 |
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | RAB9A 2078/4885KMT2A 3008/4885TDP1 529/4885 |
| US-20190183816-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | RAB9A 2120/4885KMT2A 3103/4885TDP1 499/4885 |
| US-20120214852-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | RAB9A 2120/4885KMT2A 3103/4885TDP1 499/4885 |
| US-20090326074-A1 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | RAB9A 2120/4885KMT2A 3103/4885TDP1 499/4885 |
| US-10188615-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | RAB9A 2120/4885KMT2A 3103/4885TDP1 499/4885 |
| US-20180177746-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | RAB9A 2120/4885KMT2A 3103/4885TDP1 499/4885 |
| US-20120129894-A1 | Alkoxy Compounds for Disease Treatment | ALDH1A2, CLN6, AGER | RAB9A 2120/4885KMT2A 3103/4885TDP1 499/4885 |
| US-10639286-B2 | Alkoxy compounds for disease treatment | ALDH1A2, CLN6, AGER | RAB9A 2120/4885KMT2A 3103/4885TDP1 499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.